

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb60604</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Isolation and Preliminary Characterization of a Novel scFv against SARS-CoV-2: an Experimental and Computational Analysis</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Jahandar-Lashaki</surname><given-names>Samaneh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Farajnia</surname><given-names>Safar</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Alizadeh </surname><given-names>Effat</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Seirafi</surname><given-names>Farzin</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Tanoumand</surname><given-names>Asghar</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Mohammad Kazem</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>17</volume>
      <issue>1</issue>
      <fpage>64</fpage>
      <lpage>79</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>7</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Background:&lt;/span&gt;&lt;/strong&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;Since the initial outbreak, the &lt;em&gt;SARS-CoV-2&lt;/em&gt; virus has continued to circulate and mutate, resulting in the emergence of new viral sublineages. Due to the lack of effective protection and therapeutic measures against these new variants, the virus is able to further evolve and diversify. This study aimed to screen a phage antibody library to identify monoclonal antibodies in single-chain variable fragment (scFv) format that target the Receptor Binding Domain (RBD) of different &lt;em&gt;SARS-CoV-2&lt;/em&gt; strains. The newly discovered scFv has the potential for use as a diagnostic or therapeutic option against &lt;em&gt;SARS-CoV-2&lt;/em&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Methods:&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The RBD protein was produced, purified, and used as an antigen during biopanning. Six rounds of panning enriched RBD-specific phages and the binding affinity of binders were monitored by polyclonal phage ELISA. Subsequently, monoclonal phage ELISA was employed to identify specific binders. After sequence confirmation, the reactivity of the isolated anti-RBD scFv was evaluated. Additionally, bioinformatics tools determined the interaction between selected scFv and &lt;em&gt;SARS-CoV-2&lt;/em&gt; strains.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Results:&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The ELISA analysis demonstrated that the expressed RBD retains its structural integrity and effectively interacts with antibodies present in the sera of COVID-19 patients. Through screening a phage display library, a strong-binding scFv for RBD was discovered, which can effectively neutralize &lt;em&gt;SARS-CoV-2&lt;/em&gt; and its novel variants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Conclusion:&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The findings of this study have led to the discovery of a novel scFv that effectively neutralizes &lt;em&gt;SARS-CoV-2&lt;/em&gt; strains, offering immense potential for research and therapy purposes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
